Anaerobic bacteria infection in cystic fibrosis airway disease

New Microbiologica

Volumn 33, Issue 3, 2010, Pages 185-194

  Lambiase, Antonietta ^a   Catania, Maria Rosaria ^a   Rossano, Fabio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anaerobic bacteria; Chronic lung infection; Cystic fibrosis

Indexed keywords

ANAEROBIC BACTERIUM; ANIMAL; CYSTIC FIBROSIS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BACTERIA, ANAEROBIC; CYSTIC FIBROSIS; HUMANS; LUNG;

EID: 77957098615     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. ANDERSON M.P., WELSH M.J. (1992). Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science. 257, 1701-1704.
2. ARMSTRONG D.S., GRIMWOOD K., CARLIN J.B., CARZINO R., GUTIERREZ J.P., HULL J., OLINSKY A., PHELAN E.M., ROBERTSON C.F., PHELAN P.D. (1997). Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 156, 1197-1204. (Pubitemid 27446528)
3. BAKARE N., RICKERTS Y., BARGON J., JUST-NUBLING G. (2003). Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses. 46, 19-23.
4. BITTAR F., RICHET H., DUBUS J.C., REYNAUD-GAUBERT M., STREMLER N., SARLES J., RAOULT D., ROLAIN J.M. (2008). Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PloSONE. 3, 2908.
5. BOUCHER R.C. (2002). An overview of the pathogenesis of cystic fibrosis lung disease. Adv. Drug Deliv. Rev. 54, 1359-1371. (Pubitemid 35375765)
6. BROOK I., FINK R. (1983). Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. Eur. J. Respir. Dis. 64, 51-57.
7. BURNS J.L., EMERSON J., STAPP J.R., YIM D.L., KRZEWINSKI J., LOUDEN L., RAMSEY B.W., CLAUSEN C.R. (1998). Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27, 158-163. (Pubitemid 28334435)
8. CIMON B., CARRERE J., CHAZALETTE J.P., VINATIER J.F., CHABASSE D., BOUCHARA J.P. (1999). Chronic airway colonization by Penicillium emersonii in a patient with Cystic Fibrosis. Med. Mycol. 37, 291-293. (Pubitemid 29364146)
9. CIMON B., CARRERE J., VINATIER J.F., CHAZALETTE J.P., CHABASSE D., BOUCHARA J.P. (2000). Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 19, 53-56.
10. th ed. Wayne, PA. CLSI Document no Ml 1-A7, 2007.
11. COENYE T., GORIS J., SPILKER T., VANDAMME P., LIPUMA J.J. (2002). Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J. Clin. Microbiol. 40, 2062-2069.
12. DAKIN C.J., NUMA A.H., WANG H., MORTON J.R., VERTZYAS CC, HENRY R.L. (2002). Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165, 904-910. (Pubitemid 34774655)
13. DEFONTAINE A., ZOUHAIR R., CIMON B., CARRERE J., BAILLY E., SYMOENS F., DIOURI M., HALLET J.N., BOUCHARA J.P. (2002). Genotyping study of Scedosporium apiospermum isolates with cystic fibrosis. J. Clin. Microbiol. 40, 2108-2114.
14. DENNING G.M., ANDERSON M.P., AMARA J.F., MARSHALL J., SMITH A.E., WELSH M.J. (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 358, 761-764.
15. DUERDEN B.I., COLEE J.G., BROWN R., DEACON A.G., HOLBROOK W.P. (1980). A scheme for the identification of clinical isolates of gram-negative anaerobic bacilli by conventional bacteriological tests. J. Med. Microbiol. 13, 231-245.
16. EDSON R.S., RESENBLATT J.E., LEE D.T., MCVEY E.A. (1982). Recent experience with antimicrobial susceptibility of anaerobic bacteria; increasing resistance to penicillin. Mayo Clin. Proc. 57, 737-741. (Pubitemid 13221587)
17. Goss C.H., OTTO K., AITKEN M.L., RUBENFELD G.D. (2002). Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care. Med. 166, 356-361.
18. GARCIA-RODRIGUEZ J.A., GARCIA-SANCHEZ J.E., MUNOZBELLIDO J.L. (1995). Antimicrobial resistance in anaerobic bacteria: current situation. Anaerobe. 1, 69-80.
19. HARRIS JK, DE GROOTE MA, SAGEL SD, ZEMANICK ET, KAPSNER R, PENVARI C, KAESS H, DETERDING R.R., ACCURSO F.J., PACE N.R. (2007). Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc. Natl. Acad. Sci. USA. 104, 20529-20533.
20. HENTZER M., TEITZEL G.M., BALZER G.J., HEYDORN A., MOLIN S., GIvsKov M., PARSEK M.R. (2001). Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 183, 5395-5401.
21. HILL D., ROSE B., PAJKOS A., ROBINSON M., BYE P., BELL S., ELKINS M., THOMPSON B., MACLEOD C., AARON S.D., HARBOUR C. (2005). Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 43, 5085-5090.
22. JEWES L.A., SPENCER R.C. (1990). The incidence of anaerobes in the sputum of patients with cystic fibrosis. J. Med. Microbiol. 31, 271-274. (Pubitemid 20124013)
23. KNOWLES M.R., BOUCHER R.C. (2002). Mucus clearance as a primary innate defense mechanism for mammalian airways. J. Clin. Invest. 109, 571-577.
24. LAMBIASE A., RAIA V., DEL PEZZO M., SEPE A., CARNOVALE V., ROSSANO F. (2006). Microbiology of airway disease in a cohort of patients with cystic fibrosis BMC. Infect. Dis. 6, 4.
25. LAMBIASE A., DEL PEZZO M., RAIA V., SEPE A., FERRI P., ROSSANO F. (2007). Chryseobacterium respiratory tract infections in patients with cystic fibrosis. J. Infect. 55, 518-523. (Pubitemid 350082468)
26. LAMBIASE A., ROSSANO F., DEL PEZZO M., RAIA V., SEPE A., DE GREGORIO F., CATANIA M.R. (2009). Sphingobacterium respiratory tract infection in patients with cystic fibrosis. BMC. Res. Notes. 2, 262.
27. LYCZAK J.B., CANNON C.L., PIER G.B. (2002). Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15, 194-222. (Pubitemid 34303763)
28. MATSUI H., GRUBB B.R., TARRAN R., RANDELL S.H., GATZY J.T., DAVIS C.W., BOUCHER R.C. (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell. 95, 1005-1015.
29. NAGY E., URBAN E., SOKI J., TERHES G., NAGY K. (2006). The place of molecular genetic methods in the diagnostics of human pathogenic anaerobic bacteria. Acta Microbiol. Immunol. Hung. 53, 183-194.
30. OHM-SMITH M.J., SWEET R.L., HADLEY W.K. (1986). Occurrence of clindamycin-resistant anaerobic bacteria isolated from cultures taken following clindamycin therapy. Antimicrob. Agents Chemoter. 30, 11-14.
31. OLIVIER K.N., WEBER D.J., LEE J.H., HANDLER A., TUDOR G., MOLINA P.L., TOMASHEFSKI J., KNOWLES M.R.; NONTUBERCULOUS MYCOBACTERIA IN CYSTIC FIBROSIS STUDY GROUP. (2003). Nontuberculous mycobacteria. II: nested cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167, 835-840.
32. PALMER K.L., BROWN S.A., WHITELEY M. (2007). Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. J. Bacteriol. 189, 4449-4455.
33. PAMUKCU A., BUSH A., BUCHDAHL R. (1995) Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmunol. 19, 10-15.
34. PANICHI G., DI ROSA R., ENRICO P., BABUDIERI S. (1990). Anaerobic bacteria and bacterial infections: perspectives on treatment and resi stance in Italy. Rev. Infect. Dis. 12, 152-156.
35. PIER G.B., GROUT M., ZAIDI T.S., OLSEN J.C., JOHNSON L.G., YANKASKAS J.R., GOLDBERG J.B. (1996). Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science. 271, 64-67.
36. PIHET M., CARRERE J., CIMON B., CHABASSE D., DELHAES L., SYMOENS F., BOUCHARA J.P. (2009). Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med. Mycol. 47, 387-397.
37. RAJAN S., SAIMAN L. (2002). Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17, 47-56. (Pubitemid 34233391)
38. RAMSEY B.W. (1996). Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335, 179-188. (Pubitemid 26249456)
39. ROGERS G.B., CARROLL M.P., SERISIER D.J., HOCKEY P.M., JONES G., BRUCE K.D. (2004). Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 42, 5176-5183.
40. ROGERS G.B., CARROLL M.P., SERISIER D.J., HOCKEY P.M., JONES G., KEHAGIA V., CONNETT G.J., BRUCE K.D. (2006). Use of 16S rRNA profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J. Clin. Microbiol. 44, 2601-2604.
41. ROSENFELD M., GIBSON R.L., MCNAMARA S., EMERSON J., BURNS J.L., CASTILE R., HIATT P., MCCOY K., WILSON C.B., INGLIS A., SMITH A., MARTIN T.R., RAMSEY B.W. (2001). Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmunol. 32, 356-366. (Pubitemid 33015652)
42. SAIMAN L., SIEGEL J. (2004). Infection Control in Cystic Fibrosis. Clin. Microbiol. Rev. 17, 57-71.
43. SHEIKH W., PITKIN D.H., NADLER H. (1993). Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centres. Clin. Infect. Dis. 16, 361-366.
44. TAI A., RANGANATH S. (2008). Anaerobic bacterial infection in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 178, 994.
45. TAN K., CONWAY S.P., BROWNLEE K.G., ETHERINGTON C., PECKHAM D.G. (2002). Alcaligenes infection in cystic fibrosis. Pediatr. Pulmonol. 34, 101-104.
46. THOMASSEN M.J., KLINGER J.D., BADGER S.J., VAN HEECKEREN D.W., STERN R.C. (1984). Cultures of thoracotomy confirm usefulness of sputum cultures in cystic fibrosis. J. Pediatr. 104, 352-356.
47. TUNNEY M.M., FIELD T.R., MORIARTY T.E., PATRICK S., DOERING G., MUHLEBACH M.S., WOLFGANG M.C., BOUCHER R., GILPIN D.F., MCDOWELL A., ELBORN J.S. (2008). Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177, 995-1001.
48. WELSH M.J., SMITH A.E. (1993). Molecular Mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73, 1251-1254. (Pubitemid 23201140)
49. WEXLER H.M., FINEGOLD S.M. (1988). In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob. Agents Chemoter. 32 (3), 403-406.
50. WEXLER H.M., MOLITORIS E., FINEGOLD S.M. (1993). In vitro activity of Bay Y3118 against anaerobic bacteria. Antimicrob. Agents Chemother. 37 (11), 2509-2513. (Pubitemid 23324487)
51. WORLITZSCH D., TARRAN R., ULRICH M., SCHWAB U., CEKICKI A., MEYER K.C., BIRRER P., BELLON G., BERGER J., WEISS T., BOTZENHART K., YANKASKAS J.R., RANDELL S., BOUCHER R.C., DORING G. (2002). Effects of reduced mucus oxygen concentration in airway Pseudomonas infection of cystic fibrosis patients. J. Clin. Invest. 109 (3), 317-325.
52. WORLITZSCH D., RJNTELEN C., BOHM K., WOLLSCHLAGER B., MERKEL N., BORNEFF-LIPP M., DORING G. (2009). Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin. Microbiol. Infect. 15 (5), 454-460.
53. YOON S.S., HENNIGAN R.F., HILLIARD G.M., OCHSNER U.A., PARVATIYAR K., KAMANI M.C., ALLEN H.L., DEKIEVIT T.R., GARDNER P.R., SCHWAB U., ROWE J.J., IGLEWSKI B.H., MCDERMOTT T.R., MASON R.P., WOZNIAK D. J., HANCOCK R.E., PARSEK M.R., NOAH T.L., BOUCHER R.C., HASSETT D.J. (2002). Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev. Cell. 3 (4), 593-603.